Search Results - "Schumacher, T.N.M"

(Neo-)adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma – updated relapse free survival (RFS) data from the OpACIN trial and first biomarker analyses by Rozeman, E.A., Fanchi, L., van Akkooi, A.C.J., Kvistborg, P., Thienen, J.V., Stegenga, B., Lamon, B., Haanen, J.B., Schumacher, T.N.M., Blank, C.U.

Get full text

Nivolumab, ipilimumab and COX2-inhibition in early stage colon cancer by Chalabi, M., Van Leerdam, M., Aalbers, A., Van den Berg, J., Beets, G., Grootscholten, C., Snaebjornsson, P., Kuiper, M., Den Hartog, P., Weeber, F., Dijkstra, K., Kok, M., Cullen, D., Schumacher, T.N.M., Haanen, J.B., Voest, E.

Get full text

Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial by Kok, M., Horlings, H.M., van de Vijver, K., Wiersma, T., Russell, N., Voorwerk, L., Sikorska, K., van Werkhoven, E., Mandjes, I.A., Kemper, I., Foekema, J., Wilgenhof, S., Chalabi, M., Stouthard, J., Sonke, G.S., Cullen, D., Salgado, R., Schumacher, T.N.M., Blank, C.U., Linn, S.C.

Get full text

GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial by Quaak, S.G.L., van den Berg, J.H., Toebes, M., Schumacher, T.N.M., Haanen, J.B.A.G., Beijnen, J.H., Nuijen, B.

“…For the treatment of melanoma DNA vaccines are a promising therapeutic approach. In our institute a plasmid encoding a melanoma-associated epitope (MART-1) and…”
Get full text

Differentiation of CMV-specific CD8 POS T lymphocytes in primary CMV infection after renal transplantation by ten Berge, I.J.M., Gamadia, L.E., Remmerswaal, E.B.M., Surachno, S., Weel, J.F.L., Toebes, M., Schumacher, T.N.M., van Lier, R.A.W.

Get full text

Differentiation of CMV-specific CD8POS T lymphocytes in primary CMV infection after renal transplantation by TEN BERGE, I. J. M, GAMADIA, L. E, REMMERSWAAL, E. B. M, SURACHNO, S, WEEL, J. F. L, TOEBES, M, SCHUMACHER, T. N. M, VAN LIER, R. A. W

Get full text

Circumventing T-cell Tolerance to Tumour Antigens by Kessels, H.W.H.G., de Visser, K.E., Kruisbeek, A.M., Schumacher, T.N.M.

“…During past decades, many attempts have been made to induce or enhance tumour-specific T-cell immunity in cancer patients by vaccination. However, it has…”
Get full text

CMV-specific CD8pos T lymphocyte differentiation in latent CMV infection by Gamadia, L.E, Rentenaar, R.J, Remmerswaal, E.B.M, Surachno, S, Weel, J.F.L, Toebes, M, Schumacher, T.N.M, van Lier, R.A.W, ten Berge, I.J.M

Get full text